Although the co-occurrence of NRAS mutations and AML1/ETO expression remains elusive, all of these reports suggest that KIT mutants play important roles in CBF leukemia, with negative impacts on the clinical course [65,66,68,69]. This evidence concerns the gene KIT and leukemia.